Document 0193
 DOCN  M9550193
 TI    L-2-oxothiazolidine-4-carboxylic acid (procysteine) inhibits expression
       of the human immunodeficiency virus and expression of the interleukin-2
       receptor alpha chain.
 DT    9505
 AU    Lederman MM; Georges D; Dando S; Schmelzer R; Averill L; Goldberg D;
       Department of Medicine, Case Western Reserve University School of;
       Medicine, Cleveland, OH 44106-4984.
 SO    J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):107-15.
       Unique Identifier : AIDSLINE MED/95135988
 AB    These studies were undertaken to examine the in vitro effects of the
       cysteine pro-drug L-2-oxothiazolidine-4-carboxylic acid (Procysteine) on
       human immunodeficiency virus expression. Procysteine inhibited HIV
       expression in human peripheral blood mononuclear cells as detected by
       measurement of supernatant core antigen. In transient transfection
       assays, Procysteine inhibited gene expression controlled by the HIV-1
       promoter in activated Jurkat cells but not in resting Jurkat cells.
       Gel-shift assays showed that Procysteine inhibited NF-kappa B DNA
       binding activity in nuclear extracts. Procysteine did not affect the
       production of interleukin-2 by peripheral blood mononuclear cells of
       healthy HIV-seronegative subjects, as measured by bioassay but it
       decreased the density of cell-surface interleukin-2 receptors detected
       by flow cytometry after stimulation with phytohemagglutinin (PHA). Thus,
       Procysteine inhibits HIV expression, HIV promoter activity, and NF-kappa
       B binding activity in vitro. Procysteine does not affect interleukin-2
       production but inhibits interleukin-2 receptor expression in
       PHA-stimulated peripheral blood mononuclear cells.
 DE    Cells, Cultured  Dose-Response Relationship, Drug  Gene Expression/DRUG
       EFFECTS  Human  HIV Core Protein p24/ANALYSIS  HIV Infections/*VIROLOGY
       HIV-1/*DRUG EFFECTS/GROWTH & DEVELOPMENT/GENETICS
       Interleukin-2/PHARMACOLOGY  Leukocytes, Mononuclear/*VIROLOGY
       Lymphocyte Transformation/DRUG EFFECTS  NF-kappa B/METABOLISM
       Phytohemagglutinins/PHARMACOLOGY  Promoter Regions (Genetics)  Protein
       Binding  Receptors, Interleukin-2/BIOSYNTHESIS/*DRUG EFFECTS  Support,
       Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.  T-Lymphocytes/VIROLOGY
       Thiazoles/*PHARMACOLOGY  Virus Replication/DRUG EFFECTS  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).